# Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

> **NCT00928642** · PHASE2 · COMPLETED · sponsor: **Henry M. Jackson Foundation for the Advancement of Military Medicine** · enrollment: 8 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** imatinib mesylate by mouth
- **DRUG:** Gemcitabine Intravenous

## Key facts

- **NCT ID:** NCT00928642
- **Lead sponsor:** Henry M. Jackson Foundation for the Advancement of Military Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928642, "Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00928642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*